Noliterax (Indapamide, Perindopril Arginine)

Noliterax is used in the management of hypertension, targeting elevated blood‑pressure pathways.

• Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary high blood pressure.
• Hypertension requiring combination therapy: provides additive blood‑pressure control when monotherapy with an ACE inhibitor or diuretic alone is insufficient.
• Salt‑sensitive or volume‑dependent hypertension: improves control by adding a thiazide‑like diuretic to the ACE‑inhibitor regimen.

• Indapamide acts on the distal renal tubule to inhibit sodium‑chloride reabsorption, promoting diuresis and reducing plasma volume. Perindopril arginine is a prodrug that is converted to perindopril, an angiotensin‑converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II, leading to vasodilation and decreased peripheral resistance. The combined actions result in additive reduction of arterial blood pressure.

Noliterax may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Dizziness or light‑headedness, especially after the first dose.
• Headache, often mild to moderate.
• Cough, a typical ACE‑inhibitor related symptom.
• Increased urinary frequency due to the diuretic component.
• Electrolyte disturbances such as low potassium or sodium.
• Fatigue or general weakness.

Serious or Rare Side Effects

• Angioedema, including swelling of the face, lips, tongue, or airway.
• Severe hypotension, particularly in patients with volume depletion.
• Acute renal impairment or worsening of existing kidney disease.
• Hyperkalemia, especially when combined with potassium‑sparing agents.
• Pancreatitis or severe allergic reactions.
• Blood dyscrasias such as neutropenia or thrombocytopenia.

Before initiating Noliterax, several safety considerations should be addressed.

• Blood pressure monitoring: regularly assess to avoid excessive hypotension.
• Renal function: evaluate serum creatinine and eGFR before and during therapy.
• Electrolyte balance: check potassium and sodium levels, especially in patients on other diuretics.
• Pregnancy: avoid use; classified as category D due to fetal risk.
• Elderly patients: start at lower doses and monitor for orthostatic symptoms.
• Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Noliterax can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Concurrent use of other ACE inhibitors or angiotensin‑II receptor blockers, which may increase risk of renal dysfunction and hyperkalemia.
• Potassium‑sparing diuretics or potassium supplements, leading to dangerous hyperkalemia.
• Aliskiren in patients with diabetes, heightening the risk of renal impairment.
• Lithium, as ACE inhibition can increase lithium levels and toxicity.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs), which may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Loop or thiazide diuretics, which may exacerbate electrolyte disturbances.
• Other antihypertensive agents, potentially causing additive hypotensive effects.
• Antidiabetic medications, as improved blood pressure control can enhance insulin sensitivity and affect glucose levels.